SCHEMBL5545348

SCHEMBL5545348

CCCOC(=O)c1ccc(N[C]=O)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 11/20 0.60
HPGD P15428 6/20 0.60
TDP1 Q9NUW8 2/20 0.60
ESR1 P03372 1/20 0.60
CHRM1 P11229 1/20 0.60
TSHR P16473 1/20 0.60
SLC6A2 P23975 1/20 0.60
KDR P35968 1/20 0.60
SMN1; SMN2 Q16637 5/20 0.58
RAB9A P51151 6/20 0.57
LMNA P02545 3/20 0.57
MAPT P10636 4/20 0.55
MEN1 O00255 3/20 0.55
KMT2A Q03164 3/20 0.55
THRB P10828 1/20 0.55
NPC1 O15118 5/20 0.54
GAA P10253 1/20 0.54
RECQL P46063 1/20 0.54
MAPK1 P28482 1/20 0.51
USP2 O75604 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7532522 0.91 HPGD (0.67) ALDH1A1HPGDESR1TSHRSMN1; SMN2
SCHEMBL6934596 0.88 ALDH1A1 (0.62) ALDH1A1HPGDESR1TSHRSMN1; SMN2
SCHEMBL5536709 0.87 HPGD (0.59) ALDH1A1HPGDESR1TSHRSMN1; SMN2
SCHEMBL49950 0.82 ALDH1A1 (0.84) ALDH1A1HPGDTDP1ESR1CHRM1
SCHEMBL5547669 0.82 ALDH1A1 (0.64) ALDH1A1HPGDTDP1ESR1CHRM1
SCHEMBL11153196 0.81 ALDH1A1 (0.66) ALDH1A1HPGDTDP1ESR1CHRM1
SCHEMBL28758641 0.80 ALDH1A1 (0.81) ALDH1A1HPGDTDP1ESR1CHRM1
SCHEMBL27667930 0.80 ALDH1A1 (0.81) ALDH1A1HPGDTDP1ESR1CHRM1
SCHEMBL27647586 0.80 ALDH1A1 (0.81) ALDH1A1HPGDTDP1ESR1CHRM1
SCHEMBL27647510 0.80 ALDH1A1 (0.81) ALDH1A1HPGDTDP1ESR1CHRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 ALDH1A1 355/4885HPGD 3159/4885TDP1 4666/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.